Viewing Study NCT00055432

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:01 PM
Ignite Modification Date: 2026-02-26 @ 5:47 AM
Study NCT ID: NCT00055432
Status: TERMINATED
Last Update Posted: 2006-09-15
First Post: 2003-03-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
Sponsor: Eli Lilly and Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
None Peritoneal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None recurrent ovarian cancer View
None platinum-resistant View
None platinum-sensitive View
None folate receptor antagonist View